Enanta Pharmaceuticals has linked its respiratory syncytial virus (RSV) antiviral to significant reductions in viral load and ...

Enanta Pharmaceuticals' EDP-323 shows promising Phase 2a trial results, significantly reducing RSV viral load and symptoms ...

Enanta Pharmaceuticals announced positive topline results from a Phase IIa trial of EDP-323, its RSV replication inhibitor, ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Enanta Pharmaceuticals (ENTA – Research ...

In a report released today, Roy Buchanan from JMP Securities reiterated a Buy rating on Enanta Pharmaceuticals (ENTA – Research Report), ...

Enanta Pharmaceuticals Announces Positive Topline Results for EDP-323 in a Phase 2a Human Challenge Study of Healthy Adults Infected With RSV ...

Watertown, Massachusetts Saturday, September 28, 2024, 18:00 Hrs [IST] ...

New data show Talvey’s potential in multiple myeloma drug combinations. Elsewhere, AbbVie got more positive Parkinson’s drug ...

Discover Enanta Pharmaceuticals' groundbreaking patent for HBV-inhibiting compounds, offering new hope for effective hepatitis B treatments and improved patient outcomes.

Check the time stamp on this data. Updated AI-Generated Signals for Enanta Pharmaceuticals Inc. (ENTA) available here: ENTA.

More than 39 million people around the world could die from antibiotic-resistant infections over the next 25 years, according to a study published in The Lancet.  The new study by the Global Research ...

The U.S. FDA has approved Cobenfy, a dual M1/M4 muscarinic agonist that offers a fundamentally different approach to treating schizophrenia. The fixed dose combination of xanomeline-trospium is the ...